In Brief This Week: Bio-Rad; Fitch, Abbott; Gentris; Indiana Biosciences Research Institute; Strand Life Sciences; Oncospire Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said in its recently filed Form 10-Q that it identified errors in financial statements starting in 2008 through the second quarter of 2013 related to the valuation of finished goods inventory in the company's Life Science segment. It expensed inventory in amounts greater than actual costs for non-sales transactions. To correct for the errors, it has increased net income in full-year 2008 by $600,000; in 2009 by $800,000; in 2010 by $700,000; in 2011 by $800,000; and in 2012 by $1.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.